Leerink Partners Rates Definium Therapeutics (DFTX) buy

Leerink Partners reaffirmed its buy rating for Definium Therapeutics, setting a price target of $52, a 23.43% upside from the current price.

By EarningsIQ Research Desk · Published Jun 22, 2026, 2:01 PM EDT · Updated Jun 25, 2026, 2:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Leerink Partners rated Definium Therapeutics, Inc. ($DFTX) "buy" with a $52 price target on June 22, 2026.

Since the rating, $DFTX is up 26.9% after 1 week, up 19.1% after 1 month and down 12.5% to date (from the $36.67 close on Jun 22, 2026).

DFTX Definium Therapeutics, Inc.

$32.10 +135.34% year to date

Daily close · Oct 16, 2026

Key Points

On June 22, 2026, Leerink Partners reiterated its buy rating for Definium Therapeutics, Inc. (DFTX), with a price target of $52.
Leerink Partners's $52 price target implies 23.43% upside from Definium Therapeutics, Inc.'s ($DFTX) current $42.13 share price.
Definium's stock price sits at $42.13, an increase from its previous close of $38.81, reflecting strong investor interest.
Seventeen analysts currently cover Definium, with a consensus rating of 'strong buy' and a mean price target of approximately $71.65.

Get $DFTX trade alerts by text

We text you when insiders, Congress or big funds trade $DFTX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Definium Therapeutics, Inc. alert may contain errors. Disclosures

Leerink Partners Reiterates Buy Rating

On June 22, 2026, Leerink Partners reiterated its buy rating for Definium Therapeutics, Inc. (DFTX) on the NasdaqGS, setting a price target of $52. The stock is currently trading at $42.13, which is up from its prior close of $38.81.

Analyst rating track record

Leerink Partners vs. the S&P 500

YTD return +41.30% hypothetical

All-time return +41.30% S&P 500 +7.89%

vs. S&P 500 +33.41% ahead of the index

Hypothetical returns from Leerink Partners's disclosed trades, not real profit or advice. How we model this.

Analysts Set New Price Targets

Leerink's reaffirmation comes as Definium continues to attract attention in the healthcare sector, particularly in biotechnology. The company focuses on developing treatments for brain health disorders, with its lead product candidates currently in various stages of clinical trials. The stock's upward movement suggests a positive outlook from investors following recent developments.

Other Analyst Insights

Definium has caught the eye of several other analysts as well. On October 9, 2026, JP Morgan initiated coverage with an Overweight rating and a price target of $84. Canaccord Genuity maintained a Buy rating with a target of $78, up from a previous target of $64, on September 15, 2026. Additionally, Baird also maintained an Outperform rating with a target increase to $79 from $75 on the same day. Overall, the consensus among the 17 analysts is a strong buy recommendation, with a mean price target of about $71.65.

Recent Insider Transactions

Insider activity at Definium has been notable, with several executives selling shares on June 25, 2026. Chief Financial Officer Brandi Roberts sold 3,013 shares valued at about $135,675. Chief Commercial Officer Matthew Wiley sold 2,867 shares worth approximately $129,101. Chief Legal Officer Mark Sullivan sold 13,008 shares totaling around $585,750, while Chief Medical Officer Daniel Karlin sold 10,035 shares valued at about $451,876. These transactions were made under planned trading arrangements.

What Definium Therapeutics, Inc. Does

Definium Therapeutics, Inc. is a clinical biopharmaceutical company based in New York. It develops novel product candidates aimed at treating brain health disorders. The lead candidate, DT120, is in phase 3 trials for generalized anxiety disorder and major depressive disorder, while DT402 is in phase 2a trials for autism spectrum disorder. This focus on innovative treatments is likely a key factor in the ongoing analyst support.

What’s Next for Definium

Investors may look forward to the next earnings report scheduled for November 5, 2026. As a reminder, the recent analyst ratings and insider transactions reflect past activities and may not indicate current market conditions. The recent reaffirmation of the buy rating from Leerink Partners is a positive sign for Definium's ongoing efforts in the biopharmaceutical space.

12-month forecast